GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

Introduction

Type 2 diabetes significantly elevates heart failure risk, creating urgent need for treatments offering dual cardioprotective benefits. This research compared hospitalization risks among three major medication classes: glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) through innovative target trial methodology.

Research Methodology

Scientists emulated two target trials using comprehensive Swedish health data (2010-2021). The first trial included 32,979 adults initiating either GLP-1RA or DPP-4i therapy, while the second involved 30,104 patients starting GLP-1RA or SGLT-2i treatment. Researchers tracked heart failure hospitalizations as the primary outcome, using advanced Cox regression models and inverse probability weighting to balance 72 clinical variables including age, comorbidities, and medication history. The analysis examined both the overall GLP-1RA class and specific agents like liraglutide and semaglutide.

Key Findings on Heart Failure Risk

Patients beginning GLP-1RA therapy showed significantly lower heart failure hospitalization rates compared to DPP-4i starters (3.4% vs. 4.3% absolute risk over 3 years). Statistical analysis revealed a weighted hazard ratio of 0.77 (95% CI: 0.66-0.91), indicating 23% relative risk reduction. When comparing GLP-1RAs against SGLT-2is, risks proved statistically similar (3.6% vs. 3.3%) with a hazard ratio of 1.02 (CI: 0.85-1.18). The protective effect appeared strongest in patients with established heart failure or multiple cardiovascular risk factors at baseline.

Broader Cardiovascular Implications

Supporting these findings, GLP-1RA use also reduced major adverse cardiovascular events (MACE) compared to DPP-4 inhibitors (weighted HR: 0.85; CI: 0.74-0.99). This consistency across primary and secondary outcomes strengthens the evidence for GLP-1RA cardioprotection. Both intention-to-treat and per-protocol analyses confirmed these patterns across various patient subgroups, with similar results observed for individual GLP-1RA agents.

Clinical Relevance and Application

These real-world findings suggest GLP-1RAs may offer superior heart failure protection over DPP-4 inhibitors while matching the established cardiovascular benefits of SGLT-2 inhibitors. For patients with type 2 diabetes and high heart failure risk, GLP-1RAs present a viable therapeutic option. This supports recent guideline recommendations prioritizing medications with proven cardiovascular benefits. The differential effects between drug classes highlight the importance of personalized treatment selection based on individual cardiovascular risk profiles.

Conclusion

This comprehensive analysis demonstrates GLP-1 receptor agonists significantly reduce heart failure hospitalizations compared to DPP-4 inhibitors in routine type 2 diabetes management, while showing comparable cardiovascular protection to SGLT-2 inhibitors. These findings should inform both primary and secondary prevention strategies, particularly for high-risk diabetes patients who stand to benefit most from targeted cardiovascular risk reduction.